The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Survival improvement for patients with metastatic colorectal cancer over twenty years
Open accessAbstract
Over the past two decades of successive clinical trials in metastatic colorectal cancer (CRC), the median overall survival of both control and experimental arms has steadily improved. However, the incremental change in survival for metastatic CRC patients not treated on trial has not yet been quantified. We performed a retrospective review of 1420 patients with de novo metastatic CRC who received their primary treatment at the University of Texas M.D. Anderson Cancer Center (UTMDACC) from 2004 through 2019. Median OS was roughly stable for patients diagnosed between 2004 and 2012 (22.6 months) but since has steadily improved for those diagnosed in 2013 to 2015 (28.8 months), and 2016 to 2019 (32.4 months). Likewise, 5-year survival rate has increased from 15.7% for patients diagnosed from 2004 to 2006 to 26% for those diagnosed from 2013 to 2015. Notably, survival improved for patients with BRAF V600E mutant as well as microsatellite unstable (MSI-H) tumors. Multivariate regression analysis identified surgical resection of liver metastasis (HR = 0.26, 95% CI, 0.19–0.37), use of immunotherapy (HR = 0.44, 95% CI, 0.29–0.67) and use of third line chemotherapy (regorafenib or trifluridine/tipiracil, HR = 0.74, 95% CI, 0.58–0.95), but not year of diagnosis (HR = 0.99, 95% CI, 0.98–1), as associated with better survival, suggesting that increased use of these therapies are the drivers of the observed improvement in survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the median overall survival (OS) for mCRC now exceeds 32 months, an improvement from 22.6 months in 2012 [11].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [11]
In the citing paper
“The overall percent of mCRC patients treated with FOLFOX or FOLFIRI has not diminished even as the introduction of targeted therapies since 2012 has improved OS [11].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [11]
In the citing paper
“Improvements in precision therapy for mCRC have yielded impressive gains in survival with median overall survival (OS) for mCRC now exceeding 32 months [11]”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [11]
In the citing paper
“Due to the small number of individuals eligible for curative treatment, survival parameters improved modestly and mostly in patients treated in clinical trials. These patients were usually young, fit, had favourable biomarkers or had access to immunotherapeutic approaches10.”
From Current and emerging concepts for systemic treatment of metastatic colorectal cancer (2025) · cites this paper as [10]
In the citing paper
“Further improvement of overall survival was mainly achieved by addition of targeted agents.10”
From Current and emerging concepts for systemic treatment of metastatic colorectal cancer (2025) · cites this paper as [10]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421
Umar, A., Boland, C. R., Terdiman, J. P., Syngal, S., Chapelle, A. D. L., Ruschoff, J., Fishel, R., Lindor, N. M., Burgart, L. J., Hamelin, R., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh034 · Cited by 3,183
The Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,169
Self-citationPembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
André, T., Shiu, K.-K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C., Smith, D., Garcia-Carbonero, R., Benavides, M., Gibbs, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2017699 · Cited by 3,099
Overman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30422-9 · Cited by 2,836
Self-citationOverman, M. J., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.9901 · Cited by 2,079
Self-citationLandon, M., Saam, J., Brown, K. L., Moyes, K., Evans, B., & Wenstrup, R. (2015) · Oncology · doi:10.1159/000430097 · Cited by 1,939
Research works printed but not linked: 1
- Abdalla, E. K. et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann. Surg. 239, 818–825 (2004). · DOI · Paper page
Cited by
The immune microenvironment of colorectal cancer
Kennel, K. B., & Greten, F. R. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00872-1 · Cited by 140
Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma
Yousef, A., Yousef, M., Chowdhury, S., Abdilleh, K., Knafl, M., Edelkamp, P., Alfaro-Munoz, K., Chacko, R., Peterson, J., Smaglo, B. G., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00505-0 · Cited by 93
Self-citationRecent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment
Gmeiner, W. H. (2024) · Cancers · doi:10.3390/cancers16051029 · Cited by 78
“The overall percent of mCRC patients treated with FOLFOX or FOLFIRI has not diminished even as the introduction of targeted therapies since 2012 has improved OS [11].”
BackgroundInfluentialTotal neoadjuvant therapy in rectal cancer: the evidence and expectations
Boublíková, L., Novakova, A., Simsa, J., & Lohynská, R. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104196 · Cited by 63
Johnson, D., Chee, C. E., Wong, W., Lam, R. C. T., Tan, I. B. H., & Ma, B. B. Y. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102700 · Cited by 52
Metadata
- Authors
- Zeineddine, F. A., Zeineddine, M. A., Yousef, A., Gu, Y., Chowdhury, S., Dasari, A., Huey, R. W., Johnson, B., Kee, B., Lee, M. S., Morelli, M. P., Morris, V. K., Overman, M. J., Parseghian, C., Raghav, K., Willis, J., Wolff, R. A., Kawaguchi, Y., Vauthey, J.-N., Sun, R., Kopetz, S., & Shen, J. P.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Shen, John Paul
- ORCID
- Zeineddine, Fadl A.
- Zeineddine, Mohammad A.
- Yousef, Abdelrahman
- Gu, Yue
- Chowdhury, Saikat
- Dasari, Arvind
- Huey, Ryan W.
- Johnson, Benny
- Kee, Bryan
- Lee, Michael S.
- Morelli, Maria Pia
- Morris, Van K.
- Overman, Michael J.
- Parseghian, Christine
- Raghav, Kanwal
- Willis, Jason
- Wolff, Robert A.
- Kawaguchi, Yoshikuni
- Vauthey, Jean-Nicolas
- Sun, Ryan
- Kopetz, Scott
- Shen, John Paul
- Venue
- npj Precision Oncology
- Published
- 2023-02-13
- Volume
- 7
- Issue
- 1
- Pages
- 16-16
- ISSN
- 2397-768X (ISSN-L)
- PMC
- PMC9925745
- OpenAlex
- W4320481117
- Cited by
- 192
- References
- 65
- Citations by year
- 2026: 56 · 2025: 68 · 2024: 51 · 2023: 16
- FWCI
- 23.30
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- npj Precision Oncology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Cancer Prevention and Research Institute of Texas
- U.S. Department of Health & Human Services | NIH | National Cancer Institute (SPORE P50CA221707)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
- Keywords
- metastatic colorectal cancer, survival improvement, hepatectomy, immunotherapy, regorafenib, trifluridine/tipiracil, BRAF V600E mutation, microsatellite instability, third-line chemotherapy, year of diagnosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Survival improvement for patients with metastatic colorectal cancer over twenty years. https://app.cochat.ai/papers/10.1038/s41698-023-00353-4
- The paper
- Zeineddine, F. A., Zeineddine, M. A., Yousef, A., Gu, Y., Chowdhury, S., Dasari, A., Huey, R. W., Johnson, B., Kee, B., Lee, M. S., Morelli, M. P., Morris, V. K., Overman, M. J., Parseghian, C., Raghav, K., Willis, J., Wolff, R. A., Kawaguchi, Y., Vauthey, J.-N., . . . Shen, J. P. (2023). Survival improvement for patients with metastatic colorectal cancer over twenty years. npj Precision Oncology. https://doi.org/10.1038/s41698-023-00353-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.